<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884832</url>
  </required_header>
  <id_info>
    <org_study_id>08-005892</org_study_id>
    <secondary_id>R01DK078924</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT00884832</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study of Clonidine for Fecal Incontinence.</brief_title>
  <official_title>A Placebo-Controlled Study of Clonidine for Fecal Incontinence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic
      are doing a research study to assess the effects of a medication, clonidine, on fecal
      incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug
      Administration (FDA) for treating high blood pressure, but not for treating incontinence and
      rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence,
      increase rectal capacity and reduce rectal sensation to a greater extent than placebo in
      women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Available therapeutic options for idiopathic fecal incontinence (FI) are limited and
      unsatisfactory. In addition to weak anal sphincters, our data suggest that reduced rectal
      capacity may contribute to rectal hypersensitivity and the symptom of rectal urgency in FI.
      During a 4 week study, oral clonidine restored rectal capacity and improved fecal continence
      in women with urge-predominant FI. Clonidine improves fecal continence and stool consistency
      in diarrhea-predominant irritable bowel syndrome (IBS). Therefore, we now propose a
      placebo-controlled study of clonidine for FI. Our aims are to (i) compare the effects of
      clonidine and placebo, to be given for 4 weeks, on symptoms, anal pressures, rectal
      compliance and sensation in women with FI. Forty four women (18-75 y) with urge predominant
      &quot;idiopathic&quot; FI and ≥ 4 episodes of FI during a 4 week screening period will be recruited to
      this study. Thereafter, patients will be treated with clonidine or placebo for 4 weeks. Bowel
      symptoms will be recorded in a diary. Anal sphincter pressures, rectal compliance and
      sensation will be evaluated before and during treatment with clonidine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Fecal Incontinence and Constipation Assessment (FICA) Score</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
    <description>The FICA severity scale has 4 items (frequency, type, amount of leakage, and presence of urgency) and is used to rate the severity of fecal incontinence. The parameter was computed from values in the weekly diaries. The FICA score can range from 1 to 13. Symptom severity scores of 1-6, 7-10, and 11-13 are categorized as mild, moderate, and severe, respectively. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days With Fecal Incontinence</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
    <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Fecal Incontinence Episodes</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
    <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Bowel Movements Which Were Incontinent</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
    <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Severity of Fecal Incontinence</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
    <description>The Fecal Incontinence Severity Index was used to compute the severity of fecal incontinence (FI). It is a validated 4-item scale used to assess the frequency of 4 different types of FI (gas, mucus, liquid stool, solid stool). The subject responses are weighted and summed for the 4 types of FI. Scores could range from 0 (no symptoms) to 61 (very frequent FI). Values were computed from pre- and post- treatment questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Fecal Incontinence on Baseline Quality of Life</measure>
    <time_frame>4 weeks baseline</time_frame>
    <description>Scores were computed from a pre-treatment questionnaire, the Fecal Incontinence Quality of Life Scale. This scale is composed of a total of 29 items; these items form four scales: Lifestyle (10 items) Coping/Behavior (9 items), Depression/Self Perception (7 items), and Embarrassment (3 items).
Scales range from 1 to 4; with a 1 indicating a lower functional status of quality of life. Scales scores are the average (mean) response to all items in the scale (that is, add the responses to all questions in a scale together and then divide by the number of items in the scale, adjusting for missing values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Fecal Incontinence on Post-Treatment Quality of Life</measure>
    <time_frame>after 4 weeks treatment</time_frame>
    <description>Scores were computed from a post-treatment questionnaire, the Fecal Incontinence Quality of Life Scale. This scale is composed of a total of 29 items; these items form four scales: Lifestyle (10 items) Coping/Behavior (9 items), Depression/Self Perception (7 items), and Embarrassment (3 items).
Scales range from 1 to 4; with a 1 indicating a lower functional status of quality of life. Scales scores are the average (mean) response to all items in the scale (that is, add the responses to all questions in a scale together and then divide by the number of items in the scale, adjusting for missing values).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Treatment</measure>
    <time_frame>4 weeks baseline, 4 week treatment</time_frame>
    <description>This parameter was determined by a 100 mm visual analog scale, with possible scores ranging from 0 = &quot;Not satisfied at all (no relief of symptoms)&quot; to 100 = &quot;Completely satisfied (symptoms resolved).&quot; The parameter was computed from weekly diaries. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bowel Movements Preceded by Rectal Urgency</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
    <description>Rectal urgency is defined as a sudden, irresistible need to have a bowel movement. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bowel Movements With Semi-formed and Loose Stools in Subjects With and Without Diarrhea</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
    <description>The percentage of bowel movements with semi-formed and loose stools was defined as those with a score of 5-7 on the Bristol stool form scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bowel Movements With Semi-formed and Loose Stools Post-treatment Adjusted for Baseline</measure>
    <time_frame>4 weeks treatment</time_frame>
    <description>The percentage of bowel movements with semi-formed and loose stools was defined as those with a score of 5-7 on the Bristol stool form scale. The &quot;adjustment for baseline&quot; was an analysis of covariance (ANCOVA) where the covariate was the baseline version of the endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Fecal Incontinence (FI)</measure>
    <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With FI Post-treatment Adjusted for Baseline</measure>
    <time_frame>4 weeks treatment</time_frame>
    <description>The &quot;adjustment for baseline&quot; was an analysis of covariance (ANCOVA) where the covariate was the baseline version of the endpoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Oral Clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
    <arm_group_label>Oral Clonidine</arm_group_label>
    <other_name>Kapvay</other_name>
    <other_name>Nexiclon</other_name>
    <other_name>Catapres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
    <arm_group_label>Oral Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-75 years with urge predominant FI, as defined by a validated
             questionnaire, for greater than or equal to 1 year duration will be eligible to
             participate

          -  Absence of organic disease (i.e., ulcerative colitis, cancer) as evidenced by
             colonoscopy, or barium enema and sigmoidoscopy within the last 3 years

        Exclusion Criteria:

          -  History of clinically significant cardiovascular or pulmonary disease or EKG
             abnormalities within the last 6 months [i.e., atrial flutter or fibrillation, sinus
             tachycardia (&gt; 110/minute) or bradycardia (&lt; 45 beats/minute), or prolonged corrected
             QT (QTc) interval (&gt; 460 msec)

          -  Current or past history of rectal cancer, scleroderma, inflammatory bowel disease,
             congenital anorectal abnormalities, greater than or equal to Grade 2 rectal prolapse,
             history of rectal resection or pelvic irradiation

          -  Neurological disorders - Spinal cord injuries, dementia (Mini-mental status score
             &lt;20/25), multiple sclerosis, Parkinson's disease, peripheral neuropathy

          -  Conditions precluding safe use of clonidine, i.e., symptomatic hypotension, or
             systolic blood pressure of &lt;100 mm Hg on initial screening visit

          -  Pregnant or nursing women

          -  Severe diarrhea during the run in phase defined as greater than 6 liquid stools daily
             (Bristol 6 or 7)

          -  Medications: Absolute - opioid analgesics, anticholinergic drugs [low doses of
             tricyclic antidepressants, e.g., nortriptyline (up to 50 mg/day) or amitriptyline (up
             to 25 mg/day) will be permitted provided they were begun 3 months prior to the
             screening period]

          -  Medications: Relative - other antihypertensive agents (i.e., if there is concern about
             synergistic effects and hypotension)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adil E Bharucha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <results_first_submitted>October 16, 2013</results_first_submitted>
  <results_first_submitted_qc>January 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2014</results_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adil Bharucha</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>fecal incontinence</keyword>
  <keyword>stool leakage</keyword>
  <keyword>incontinence</keyword>
  <keyword>FI</keyword>
  <keyword>Urge predominant fecal incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted between January 2009 and April 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Clonidine</title>
          <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Oral Placebo</title>
          <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Clonidine</title>
          <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Oral Placebo</title>
          <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="10.88"/>
                    <measurement group_id="B2" value="57" spread="11.86"/>
                    <measurement group_id="B3" value="57.38" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="1.09"/>
                    <measurement group_id="B2" value="28.0" spread="6.35"/>
                    <measurement group_id="B3" value="29.14" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hysterectomy</title>
          <description>Number of participants who had previously had a hysterectomy at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Functional diarrhea or Diarrhea-predominant Irritable Bowel Syndrome (IBS)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Subjects with diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects without diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Fecal Incontinence and Constipation Assessment (FICA) Score</title>
        <description>The FICA severity scale has 4 items (frequency, type, amount of leakage, and presence of urgency) and is used to rate the severity of fecal incontinence. The parameter was computed from values in the weekly diaries. The FICA score can range from 1 to 13. Symptom severity scores of 1–6, 7–10, and 11–13 are categorized as mild, moderate, and severe, respectively. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fecal Incontinence and Constipation Assessment (FICA) Score</title>
          <description>The FICA severity scale has 4 items (frequency, type, amount of leakage, and presence of urgency) and is used to rate the severity of fecal incontinence. The parameter was computed from values in the weekly diaries. The FICA score can range from 1 to 13. Symptom severity scores of 1–6, 7–10, and 11–13 are categorized as mild, moderate, and severe, respectively. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
          <population>Intent to treat analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="0.4"/>
                    <measurement group_id="O2" value="9.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.6"/>
                    <measurement group_id="O2" value="7.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days With Fecal Incontinence</title>
        <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days With Fecal Incontinence</title>
          <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
          <population>Intent to treat analysis</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="1"/>
                    <measurement group_id="O2" value="16" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="1"/>
                    <measurement group_id="O2" value="11" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Fecal Incontinence Episodes</title>
        <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Fecal Incontinence Episodes</title>
          <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
          <population>Intent to treat analysis</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="3"/>
                    <measurement group_id="O2" value="31" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="3"/>
                    <measurement group_id="O2" value="19" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Bowel Movements Which Were Incontinent</title>
        <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Bowel Movements Which Were Incontinent</title>
          <description>Values were averaged over 4 week baseline and 4 week treatment periods.</description>
          <population>Intent to treat analysis</population>
          <units>percentage of bowel movements</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" spread="4"/>
                    <measurement group_id="O2" value="40" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="5"/>
                    <measurement group_id="O2" value="27" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Severity of Fecal Incontinence</title>
        <description>The Fecal Incontinence Severity Index was used to compute the severity of fecal incontinence (FI). It is a validated 4-item scale used to assess the frequency of 4 different types of FI (gas, mucus, liquid stool, solid stool). The subject responses are weighted and summed for the 4 types of FI. Scores could range from 0 (no symptoms) to 61 (very frequent FI). Values were computed from pre- and post- treatment questionnaires.</description>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Severity of Fecal Incontinence</title>
          <description>The Fecal Incontinence Severity Index was used to compute the severity of fecal incontinence (FI). It is a validated 4-item scale used to assess the frequency of 4 different types of FI (gas, mucus, liquid stool, solid stool). The subject responses are weighted and summed for the 4 types of FI. Scores could range from 0 (no symptoms) to 61 (very frequent FI). Values were computed from pre- and post- treatment questionnaires.</description>
          <population>Intent to treat analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="2.7"/>
                    <measurement group_id="O2" value="37.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="2.8"/>
                    <measurement group_id="O2" value="31.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Fecal Incontinence on Baseline Quality of Life</title>
        <description>Scores were computed from a pre-treatment questionnaire, the Fecal Incontinence Quality of Life Scale. This scale is composed of a total of 29 items; these items form four scales: Lifestyle (10 items) Coping/Behavior (9 items), Depression/Self Perception (7 items), and Embarrassment (3 items).
Scales range from 1 to 4; with a 1 indicating a lower functional status of quality of life. Scales scores are the average (mean) response to all items in the scale (that is, add the responses to all questions in a scale together and then divide by the number of items in the scale, adjusting for missing values).</description>
        <time_frame>4 weeks baseline</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Fecal Incontinence on Baseline Quality of Life</title>
          <description>Scores were computed from a pre-treatment questionnaire, the Fecal Incontinence Quality of Life Scale. This scale is composed of a total of 29 items; these items form four scales: Lifestyle (10 items) Coping/Behavior (9 items), Depression/Self Perception (7 items), and Embarrassment (3 items).
Scales range from 1 to 4; with a 1 indicating a lower functional status of quality of life. Scales scores are the average (mean) response to all items in the scale (that is, add the responses to all questions in a scale together and then divide by the number of items in the scale, adjusting for missing values).</description>
          <population>Intent to treat analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lifestyle score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.2"/>
                    <measurement group_id="O2" value="2.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.1"/>
                    <measurement group_id="O2" value="1.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.2"/>
                    <measurement group_id="O2" value="2.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Embarrassment score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.2"/>
                    <measurement group_id="O2" value="2.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Fecal Incontinence on Post-Treatment Quality of Life</title>
        <description>Scores were computed from a post-treatment questionnaire, the Fecal Incontinence Quality of Life Scale. This scale is composed of a total of 29 items; these items form four scales: Lifestyle (10 items) Coping/Behavior (9 items), Depression/Self Perception (7 items), and Embarrassment (3 items).
Scales range from 1 to 4; with a 1 indicating a lower functional status of quality of life. Scales scores are the average (mean) response to all items in the scale (that is, add the responses to all questions in a scale together and then divide by the number of items in the scale, adjusting for missing values).</description>
        <time_frame>after 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Fecal Incontinence on Post-Treatment Quality of Life</title>
          <description>Scores were computed from a post-treatment questionnaire, the Fecal Incontinence Quality of Life Scale. This scale is composed of a total of 29 items; these items form four scales: Lifestyle (10 items) Coping/Behavior (9 items), Depression/Self Perception (7 items), and Embarrassment (3 items).
Scales range from 1 to 4; with a 1 indicating a lower functional status of quality of life. Scales scores are the average (mean) response to all items in the scale (that is, add the responses to all questions in a scale together and then divide by the number of items in the scale, adjusting for missing values).</description>
          <population>Intent to treat analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lifestyle score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.2"/>
                    <measurement group_id="O2" value="2.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.2"/>
                    <measurement group_id="O2" value="2.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.1"/>
                    <measurement group_id="O2" value="3.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Embarrassment score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.2"/>
                    <measurement group_id="O2" value="2.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Treatment</title>
        <description>This parameter was determined by a 100 mm visual analog scale, with possible scores ranging from 0 = &quot;Not satisfied at all (no relief of symptoms)&quot; to 100 = &quot;Completely satisfied (symptoms resolved).&quot; The parameter was computed from weekly diaries. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
        <time_frame>4 weeks baseline, 4 week treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Treatment</title>
          <description>This parameter was determined by a 100 mm visual analog scale, with possible scores ranging from 0 = &quot;Not satisfied at all (no relief of symptoms)&quot; to 100 = &quot;Completely satisfied (symptoms resolved).&quot; The parameter was computed from weekly diaries. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
          <population>Intent to treat analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="6"/>
                    <measurement group_id="O2" value="18" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="6"/>
                    <measurement group_id="O2" value="38" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bowel Movements Preceded by Rectal Urgency</title>
        <description>Rectal urgency is defined as a sudden, irresistible need to have a bowel movement. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bowel Movements Preceded by Rectal Urgency</title>
          <description>Rectal urgency is defined as a sudden, irresistible need to have a bowel movement. Scores were averaged over the 4 week baseline period and the 4 week treatment periods.</description>
          <population>Intent to treat analysis</population>
          <units>percentage of bowel movements</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="4"/>
                    <measurement group_id="O2" value="59" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="6"/>
                    <measurement group_id="O2" value="46" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bowel Movements With Semi-formed and Loose Stools in Subjects With and Without Diarrhea</title>
        <description>The percentage of bowel movements with semi-formed and loose stools was defined as those with a score of 5-7 on the Bristol stool form scale.</description>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bowel Movements With Semi-formed and Loose Stools in Subjects With and Without Diarrhea</title>
          <description>The percentage of bowel movements with semi-formed and loose stools was defined as those with a score of 5-7 on the Bristol stool form scale.</description>
          <population>Intent to treat analysis</population>
          <units>percentage of bowel movements</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline, subjects without diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="4.9"/>
                    <measurement group_id="O2" value="25.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks baseline, subjects with diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" spread="8.1"/>
                    <measurement group_id="O2" value="51.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment, subjects without diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="4.2"/>
                    <measurement group_id="O2" value="16" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment, subjects with diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="7"/>
                    <measurement group_id="O2" value="49" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportion of semi-formed and loose stools (Bristol Form 5-7) associated with diarrhea subgroup versus no diarrhea subgroup.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bowel Movements With Semi-formed and Loose Stools Post-treatment Adjusted for Baseline</title>
        <description>The percentage of bowel movements with semi-formed and loose stools was defined as those with a score of 5-7 on the Bristol stool form scale. The “adjustment for baseline” was an analysis of covariance (ANCOVA) where the covariate was the baseline version of the endpoint.</description>
        <time_frame>4 weeks treatment</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bowel Movements With Semi-formed and Loose Stools Post-treatment Adjusted for Baseline</title>
          <description>The percentage of bowel movements with semi-formed and loose stools was defined as those with a score of 5-7 on the Bristol stool form scale. The “adjustment for baseline” was an analysis of covariance (ANCOVA) where the covariate was the baseline version of the endpoint.</description>
          <population>Intent to treat analysis</population>
          <units>percentage of bowel movements</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="4.8"/>
                    <measurement group_id="O2" value="38.7" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects without diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="4.3"/>
                    <measurement group_id="O2" value="22.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>drug*group interactions</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Fecal Incontinence (FI)</title>
        <time_frame>4 weeks baseline, 4 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Fecal Incontinence (FI)</title>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks baseline, subjects without diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="5.5"/>
                    <measurement group_id="O2" value="37.8" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks baseline, subjects with diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="7.2"/>
                    <measurement group_id="O2" value="42.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment, subjects without diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="7.1"/>
                    <measurement group_id="O2" value="18.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks treatment, subjects with diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="8.5"/>
                    <measurement group_id="O2" value="33.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With FI Post-treatment Adjusted for Baseline</title>
        <description>The “adjustment for baseline” was an analysis of covariance (ANCOVA) where the covariate was the baseline version of the endpoint.</description>
        <time_frame>4 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Clonidine</title>
            <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With FI Post-treatment Adjusted for Baseline</title>
          <description>The “adjustment for baseline” was an analysis of covariance (ANCOVA) where the covariate was the baseline version of the endpoint.</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects without diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.54" spread="5.92"/>
                    <measurement group_id="O2" value="31.42" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.79" spread="6.97"/>
                    <measurement group_id="O2" value="39.51" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Clonidine</title>
          <description>Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Oral Placebo</title>
          <description>Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adil E. Bharucha</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-9156</phone>
      <email>bharucha.adil@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

